Tumor-Targeted CD40 Antibody Shows Safe Profile but Limited Tumor Shrinkage in Phase 1 Trial
RO7300490, a FAP-targeted CD40 agonist, proved manageable in 80 advanced cancer patients but produced no objective tumor responses despite clear immune activation.
